Amgen (NASDAQ:AMGN) today announced the appointment of Anna S. Richo as senior vice president, Worldwide Compliance. Richo will head the organization responsible for AmgenÂ™s corporate compliance and business ethics programs. She will report to Amgen Chairman and Chief Executive Officer Kevin Sharer.
Richo, 47, joined Amgen in 2003 and was most recently vice president, Law, responsible for worldwide management of all corporate litigation and law department operations. Prior to Amgen, she spent 12 years at Baxter Healthcare Corporation in roles of increasing responsibility in law, including vice president, Law, for BaxterÂ™s BioScience Division. Also, for more than five years Richo served on the Board of Directors of Cytyc Corporation and was a member of the Audit and Finance Committees.
As the compliance demands on biopharmaceutical companies are increasing, we want to ensure AmgenÂ™s continued excellent performance in this area in the interests of patients and all our stakeholders, said Sharer.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new scienceÂ™s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve peopleÂ™s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Cory Rivera, 805-447-1060 (investors)